In a press release dated August 5, 2020, Mayor Victorino responded to the transmission of a proposed resolution I sent to the Governance, Ethics, and Transparency Committee that would seek a settlement to the Hawaii Wildlife Fund, ET AL, v. County of Maui.

The Mayor noted that my actions are highly irresponsible and I am using the Platform to garner votes. I believe the Mayors comments are an over reaction and ill advised. The transmission of the resolution for settlement has no impact on mediation and was not submitted with the intention to interfere with on-going negotiations.

I support continued mediation to resolve this matter once and for all. The proposed resolution for settlement I transmitted will be available to the Council if mediation fails. Its important to recognize that if the past is any indication for how the county fairs in this litigation matter, settlement or negotiations, the county has been on the short end of the stick.

Over the last 8 years, numerous courts have rejected the Countys defense; past settlements have resulted in an additional 5 years of litigation at a cost of over $4 million dollars to county taxpayers in legal fees. Based on past history, Im not holding a lot of faith that mediation will be constructive, however, I am hopeful.

Relative to the Mayors comments that my actions are highly irresponsible and a platform to garner votes, these comments are mean spirited and seek to drive a wedge in collaborative government. Dragging the injection well case over 8 years costing county residents over $4 million dollars is highly irresponsible.

As far as using the platform to garner votes, I am Chair of the Governance, Ethics, and Transparency Committee, it is my job as the Committee Chair, to address settlements and litigation of the County of Maui. Am I using this platform to garner votes, NO, Im using this platform to do my job as assigned to me by the County Council.

My intention in transmitting the proposed resolution for settlement is to provide the Council with an option to end an 8-year nightmare. My focus is to preserve the environment for our future families; reduce impacts to our reef systems, maintain marine life and lessen the dependency on the use of injection wells.

Over the past few months, the county has been hit with a pandemic, the likes of which we have not seen in decades. People are sick, businesses are closing, residents have lost their jobs and people cannot afford to pay rent or mortgages. Our priorities should be to help address these concerns, not spending hundreds of thousands of dollars on attorneys fees.

During these past months, the Mayor has focused his energies on attacking the Council on charter amendments, legislative initiatives and this litigation matter. With all due respect Mr. Mayor, your priorities are wrong. Your focus should be on providing shelter, economic recovery and the health and safety of our community. You are no longer a Councilmember, you are the Mayor, your job is to administer and now is the time to show some leadership.

In May, the Mayor asked for recommendations on how to spend federal assistance for COVID-19. The Council provided excellent recommendations for assistance to our community, however, it took over 3 months for the Mayor to act on the recommendations.

Mr. Mayor, please stop the constant attacking, stop the anger, stop the talk, show some leadership and focus on the real needs of our community.

Mike Molinaholds the County Council seat for the Makawao-Haik-Pia residency area.

comments

Read the original post:
OpEd: Mayor Needs to Focus on the Real Needs of Our Community says Mike Molina - Maui Time

Rising number of corona virus cases has impacted numerous lives and led to numerous fatalities, and has affected the overall economic structure globally. The Canine Stem Cell Therapy has analyzed and published the latest report on the global Canine Stem Cell Therapy market. Change in the market has affected the global platform. Along with the Canine Stem Cell Therapy market, numerous other markets are also facing similar situations. This has led to the downfall of numerous businesses, because of the widespread increase of the number of cases across the globe.href=mailto:nicolas.shaw@cognitivemarketresearch.com>nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Request Free Sample Copy of Canine Stem Cell Therapy Market Research Report@ https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

The major players in the Canine Stem Cell Therapy market are VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet . Some of the players have adopted new strategies to sustain their position in the Canine Stem Cell Therapy market. A detailed research study is done on the each of the segments, and is provided in Canine Stem Cell Therapy market report. Based on the performance of the Canine Stem Cell Therapy market in various regions, a detailed study of the Canine Stem Cell Therapy market is also analyzed and covered in the study.

Report Scope:Some of the key types analyzed in this report are as follows: Allogeneic Stem Cells, Autologous Stem cells

Some of the key applications as follow: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Following are the major key players: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

An in-depth analysis of the Canine Stem Cell Therapy market is covered and included in the research study. The study covers an updated and a detailed analysis of the Canine Stem Cell Therapy market. It also provides the statistical information of the Canine Stem Cell Therapy market. The study of the report consists of the detailed definition of the market or the overview of the Canine Stem Cell Therapy market. Furthermore, it also provides detailed information for the target audience dealing with or operating in this market is explained in the next section of the report.

Read Detailed Index of full Research Study @: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

The report also provides detailed information on the research methodologies, which are used for the analysis of the Canine Stem Cell Therapy market. The methods are covered in detail in this section of the report. For the analysis of the market, several tools are used for the extraction of the market numbers. Among the several tools, primary and secondary research studies were also incorporated for the research study. These were further analyzed and validated by the market experts, to increase precision and make the data more reliable.

Moreover, the report also highlights and provides a detailed analysis of the drivers, restrains, opportunities, and challenges of the Canine Stem Cell Therapy market. This section of Canine Stem Cell Therapy market also covers the updated information, in accordance with the present situation of the market.

According to the estimation and the analysis of the market, the Canine Stem Cell Therapy market is likely to have some major changes in the estimated forecasts period. Moreover, these changes can be attributed to the changes due to economic and trading conditions across the globe. Moreover, several market players operating in the Canine Stem Cell Therapy market will have to strategically change their business strategies in order to survive in the market.

If Any Inquiry of Canine Stem Cell Therapy Report @: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

Reasons for Buying this Canine Stem Cell Therapy Report1. Canine Stem Cell Therapy market advertise report helps with understanding the Basic product segments alongside likewise their potential future.2. This global Canine Stem Cell Therapy report offers pin-point evaluation for changing competitive dynamics.3. The Canine Stem Cell Therapy market supplies pin point analysis of changing competition dynamics and keeps you in front of competitors4. Original images and illustrated a SWOT evaluation of large segments supplied by the Canine Stem Cell Therapy market.5. This report supplies a forward-looking perspective on different driving factors or controlling Canine Stem Cell Therapy market gain.6. This report assists to make wise business choices using whole insights of the Canine Stem Cell Therapy and also from creating a comprehensive evaluation of market sections.Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

*If you have any special requirements, please let us know and we will offer you the report as you want Click Here>Download Customized Sample Report of Canine Stem Cell Therapy Market Report 2020 (COVID-19 Impact Analysis Updated Edition May 2020)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.

Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

Read the original here:
In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Canine Stem Cell Therapy Coronavirus Impact Editon of Key Players VETSTEM...

Heres our fortnightly wrap of all the news driving ASX health stocks.

Of the ASXs 133-odd small cap health stocks and of those which were trading on Wednesday, 58 were in positive territory over the last fortnight, eight were flat and 67 saw their share prices fall.

No matter which way you cut it, the last fortnight wasnt great for markets. The Small Ords was down almost 1 per cent and the broader market was in a similar state.

Another great rotation, as pundits have taken to calling the big sector sell downs and buy-ins, did not favour health this time with Biotech Dailys Top 40 index falling 2.4 per cent when compared to an ASX200 half percentage point lift in July.

However, fortune favours the bold and investors in Aroa Biosurgery (ASX:ARX) would be pleased with their first fortnight on the market, with the stock up 97 per cent from its IPO on July 24.

Aroa is treading a now familiar path with a wound care product that combines a matrix on which cells can regrow with a treatment for diabetic foot ulcers and venous leg ulcers.

The company is following in the footsteps of Avita (ASX:AVH) and Polynovo (ASX:PNV) which are both successfully treading hospital wards around the world.

Having already put its product through clinical trials and attained US Federal Drug Administration (FDA) approval, it has avoided following the other path trodden by Factor Therapeutics (ASX:FTT), which was trying to cure the same conditions and failed badly.

However Factor is up on the list as well because its board has finally found something to buy: Brain Biosciences, a commercial-stage veterinary medical technology company in the US which is trading as LONGMILE Veterinary PET Imaging.

Chair Dr Cherrell Hirst, who led the long search for the new face of Factor, will retire at the upcoming AGM and be replaced by Dr David Brookes, a rural medicine expert and ASX biotech director.

The deal is still non-binding and subject to due diligence, but this is the first one the Factor board has felt strongly enough about to release publicly.

Its subject to demonstrating to LONGMILE shareholders that Factor has at least $3m in cash when the deal is done and sorting out the board composition, among other things.

Health software company Oneview Healthcare (ASX:ONE) rose after saying installed live devices by the end of June were up 30 per cent on a year ago, and the June quarter saw two customers renew and one extend a contract.

Suda Pharmaceutical (ASX:SUD) finally had its day, after the Therapeutic Goods Administration (TGA) approved several months earlier than unexpected its insomnia mouth spray ZolpiMist.

Suda has been working on ZolpiMist since January 2015 when it licensed zolpidem from Amherst Pharma.

Stem cell play Regeneus (ASX:RGS) has also begun generating some interest among analysts and investors.

It recently updated its negotiating status with Japanese company Kyocera for the osteoarthritis treatment Progenza.

Under the terms of an MOU signed in March, Kyocera has exclusive rights to negotiate a commercial licence for Progenza in Japan. It was supposed to end in July but with talks moving ahead well, they agreed to extend the exclusivity period to the end of August.

And Cogstate (ASX:CGS) moved further ahead with its partnership with Eisai in Japan, which has begun building the brain performance application Easiit, a base element of a digital platform for dementia, that will incorporate Cogstates NouKNOW assessment by the end of September.

Get the latest Stock & Small Caps news and insights direct to your inbox.

It's free. Unsubscribe whenever your want.

You might be interested in

Read more here:
Check up: Maybe next week will be better? - Stockhead

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

To Remain Ahead Of Your Competitors, Request for a FREE Sample Here (with covid 19 Impact Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&DW

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Make an Enquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&DW

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Read More @ https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market?Dw

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email @ [emailprotected]

Visit link:
Wound Care Biologics Market By Covid-19 Impact Analysis, Size, Regional Growth, Major Key Players, Technology And Industry Trends Till 2025 - eRealty...

Two years ago, Bustos was happy. She was 20, recently married and had just found out she was pregnant with her first child. Taylor and her husband, Mark, 21, envisioned moving from Duluth to California and raising half a dozen kids. But those plans would have to wait.

Five months into her pregnancy, Bustos felt a lump on her neck. On Oct. 5, 2018, just a month after giving birth to her son, Solomon, she was diagnosed with nodular sclerosis classical Hodgkins lymphoma. Its the most common type of Hodgkins lymphoma, a cancer that affects the bodys immune system.

I was told, This is the good cancer, its curable, Bustos said. She underwent six months of chemotherapy at St. Lukes Radiation Oncology Associates in Duluth and was declared in remission in April 2019. After that, life went pretty much back to normal.

But last November, just before her first follow-up PET CT scan, Bustos prepared for the worst. A few weeks earlier, she had felt the lump in her neck return.

Soon later, she was back at St. Lukes, prepared to receive whatever news may come. Mark tossed a bright pink ball to Solomon to distract the boy and himself from the mounting anxiety as they waited for what felt like an eternity in the small examination room.

The young father was also trying to manage his stress from recently learning he was being laid off from his construction job. The doctor finally stepped in.

Taylor and Mark shared a kiss in their kitchen, taking any quiet moment they can to show their love to one another while raising a one-year-old. Taylor had been diagnosed with Hodgkin's Lymphoma only a month after giving birth to their first son, Solomon. She had just spent the better part of a year battling cancer and was now cancer free. So she was trying to enjoy any sense of normalcy she could. Alex Kormann / Minneapolis Star Tribune/TNS

Im sitting there with a one-year-old and my husband of two years and theyre telling me at 22 years old that I have cancer for the second time, Bustos said.

She had gone into the meeting with the mindset that she would never endure chemotherapy again. It was physically and mentally unlike any other suffering Ive ever gone through in my life and I didnt want to willingly say yes to going back there, Bustos said.

After a week of thinking and praying, Bustos stumbled across a Facebook post from a friend who had recently lost his father in a house fire. His words resonated so deeply with her that she decided she couldnt just lay down and die. This cancer could kill me, but dont I want my sweet son to know I tried? she said.

Once again, she went in for treatments, then slept for three days. The big difference this time was that, to make sure the cancer never came back, she was going to have to follow the doctors next recommendation.

On March 2, the Bustos family picked up and moved 200 miles across the state to Rochester for three months where she would undergo some of the most toxic chemotherapy available at the Mayo Clinic. The mix was so potent that she had to first undergo a stem cell collection; those stem cells would be transplanted afterward to regrow her immune system and other healthy cells decimated by the chemo.

Marks layoff, which at first seemed like a disaster, was now a gift. He could assume a larger role as the family caretaker. Some people might call that luck, but the Bustoss dont believe in luck. For them, it was an act of God.

When it came time to move, Taylors parents, Pam and Jerry, who live across the street from the Bustoses in Duluth, moved with them to help take care of Solomon and Taylor.

It really wasnt a difficult decision, said Jerry, who is a warehouse operator at a Duluth paper supply business.

For me, he said, I would do whatever it takes to get her healthy.

The whole family joined hands and prayed before dinner. God and faith are extremely important to them and has helped Taylor get through this difficult chapter in her life. The COVID-19 pandemic forced church to be held via live stream so Taylor was able to follow along even from 200 miles away. Her faith helped Taylor push through even the darkest moments of treatment. "Knowing I'm in the hands of such a faithful father made it peaceful," she said. Alex Kormann / Minneapolis Star Tribune/TNS

Their family squeezed as much as they could into their two cars, boxes stacked to the roof, rendering the rearview mirror useless. The family settled into a small house only a mile away from the Mayo Clinic.

Just over a week later, COVID-19 hit.

We knew Id have a weakened immune system and wed have to quarantine, Bustos said, but suddenly the whole world had to quarantine, too.

They stayed closely connected with their church through video chat and live streams. In solidarity, her entire family shaved their heads along with Bustos.

A little over a month after moving, Bustos prepared for her most difficult round of chemotherapy. All the effects of normal chemo, including nausea, exhaustion, loss of appetite and body pain would be amplified. And because of the coronavirus, she would be doing it alone. She packed her keyboard piano, a weeks worth of clothes, a few mementos from home and headed to the hospital. She would have to stay in a heavily filtered room by herself for a full week as she underwent treatment.

Masked nurses came and went as Bustos tried to picture what they looked like under all the PPE. Most days, she felt immensely lonely and sad. Originally, she was told shed be able to go home to see her family for one hour per day. The pandemic scrapped those plans. I would cry and nurses couldnt put their hand on my shoulder to tell me, Its OK, because of the coronavirus, Bustos said.

When she was finally able to return to her family a full week later, Bustos was ecstatic. To be able to be hugged was a very welcome relief from despair, she said.

She began to try and process what had happened to her over the last five months. She felt distant from and misunderstood by nearly everyone around her. It can look like its going well from the outside but when you literally want to die, the emotional side of things needs to be handled, she said.

Bustos has since begun therapy and is taking anti-depressants to help manage her mental pain.

As the family moved out of Rochester, the snow was gone. Birds chirped and flowers bloomed; a sign of rebirth and a new beginning.

When they pulled up in front of their apartment in Duluth, chalk drawings graced their sidewalk welcoming them home. Their front door was covered in balloons and a welcome banner was strung across the door frame, all put together by members of Bustoss church youth group.

Bustos collapsed on her old bed. She thought shed feel different in their own apartment, but it oddly felt the same. She had come to realize that home was no longer a physical space. Cancer changed that.

Home for me has become Mark and Solomon, she said, and so whether were in Rochester, Duluth or Timbuktu, Im home when Im with them.

2020 Star Tribune (Minneapolis)

Visit the Star Tribune (Minneapolis) at http://www.startribune.com

Distributed by Tribune Content Agency, LLC.

More here:
In the middle of pandemic, this young mom fights second cancer diagnosis - INFORUM

Some 8.7 million years ago, much of what is now Idaho was torched by clouds of hot volcanic ash, destroying all vegetation and animals in sight. The supervolcano, Yellowstone, was erupting. This was Yellowstones largest eruption on record.

Super-eruptions can decimate entire regions, and their cocktail of ash and gases can alter the climate.But, even though they eject huge amounts of material, there are very few documented super-eruptions in the geologic record. So we dont fully understand why they are so big or how often they occur. Now, details of the Yellowstone supervolcanic eruption are documented in a new study published in the journal Geology.

Yellowstones ancient eruptions scattered volcanic debris across the northwestern US. There are so many deposits covering an area tens of thousands of square kilometers that it can be difficult to tell each eruption apart. To get around this, volcanologists collected detailed identifying information, including chemical and chronological data, on each geological deposit.

Volcanic ash from Yellowstone

Wikimedia

When they looked at the data, they found that much of the volcanic debris, which was thought previously to come from repeated smaller eruptions, had the same chemical makeup and age. In fact, these deposits were produced by two previously unrecognized super-eruptions. Both eruptions were searingly hot, and would have baked the landscape in a thick coating of molten volcanic glass. The youngest of the two, known as the Greys Landing super-eruption, is dated to roughly 8.7 million years ago, and, according to the volume of debris released, is 30% larger than all other eruptions recorded from Yellowstone.

Recognition of these events brings Yellowstone's total number of eruptions during the late Miocene to six. That makes for one eruption about every 520,000 years. Since then, however, the pace of eruptions has slowed to once every 1.5 million years.

The evidence seems to suggest that Yellowstone is slowing down. And if this trend continues, the next super-eruption won't happen for another 900,000 years. Predicting eruptions is however a risky business, and the United States Geological Survey still maintain a permanent monitoring network on Yellowstone just in case.

Here is the original post:
Antibody testing is increasing, but what do the results mean? - Massive Science

For dogs and cats suffering from osteoarthritis and not getting good results from other treatments, stem cell therapy provides another option. Its a therapy that our veterinarians can also use for treating injuries to the spinal cord, bones, ligaments, and tendons.

Stem cells are a sort of blank slate that can regenerate as any other type of cell. In stem cell therapy, your pets stem cells are taken from their bone marrow, umbilical cord blood, or fat.

Once harvested, the stem cells are then injected into the diseased or injured area. For example, a dog would have stem cells injected in his knee damaged by osteoarthritis. The expectation would be for the cells to move to the damaged tissue, suppressing inflammation, relieving pain, and growing new, healthy tissue.

Currently, we do not offer stem cell services at our Windcrest location. Please visit our nearby Talleyville Veterinary Hospital if you would like to take advantage of stem cell therapy for your pet.

If youd like more information about stem cell therapy as an option for your dog or cat, contact us today to schedule a consultation. Were also available to take care of your pets other needs, including wellness and sick care,

View original post here:
Stem Cell Therapy for Pets | Windcrest Animal Hospital ...

The GlobalAnimal Stem Cell Therapy MarketResearch Report is a helpful source of insightful data for business strategists.It provides thedeep insights into the global market revenue, market segments, competitive landscape, manufacturing, and pricing and cost structures, growth factor. The industry overview is added after a widespread study of the significant business drivers, hindering factors and future industry prospect. Animal Stem Cell Therapy report studies the present state of the market to analyze the future opportunities and risks.

Get FREE Sample Copy (including COVID19 Impact Analysis, FULL TOC, Graphs, and Tables) of this report: https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#request_sample

Animal Stem Cell Therapy Market Report Scope:

Due to COVID-19 crisis takes over the globe, we are constantly track the changes in the markets, as well as the industry behaviors of the customers worldwide and our estimate about the newest market trends and forecasts are being done after in view of the impact of this pandemic.

Get an Upto 30% Discount On Animal Stem Cell Therapy Market Report, Do Inquiry Here: https://www.globalmarketers.biz/discount_inquiry/discount/130268

Global Animal Stem Cell Therapy Market Segmentation:

By Type:

DogsHorsesOthers

By Application:

Veterinary HospitalsResearch Organizations

The Global Animal Stem Cell Therapy Market report includes the precisely studied and assessed statistics of the key vendor and their scope in the market utilizing several analytical tools. The Porters five forces analysis, SWOT analysis, feasibility study, and investment return breakdown and used to analyze the growth of key vendors in the market. Moreover, the report presents a 360-degree overview of the competitive.

Enquire Before Buying : https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#inquiry_before_buying

Influence of the Animal Stem Cell Therapy Market report:

Animal Stem Cell Therapy MarketReport:

The Animal Stem Cell Therapy Market Report Addresses the Following Queries:

Table of Contents: Animal Stem Cell Therapy Market

Chapter 1: Overview of Animal Stem Cell Therapy Market

Chapter 2:Global Market Status and Forecast by Regions, Type

Chapter 3:Global Animal Stem Cell Therapy Market Status and Forecast by Downstream Industry

Chapter 5:Market Driving Factor Analysis

Chapter 6:Market Competition Status by Major Key Vendors

Chapter 7:Upstream and Downstream Animal Stem Cell Therapy Market Analysis

Chapter 8:Cost and Gross Margin Analysis

Chapter 9:Marketing Status Analysis

Chapter 10:Animal Stem Cell Therapy Market Report Conclusion

For more Information or Browse the complete report @ https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#table_of_contents

Read more:
Global Animal Stem Cell Therapy Market Report 2020 By Key Players, Trends, Countries, Market Size, Forecast To 2024 (based On 2020 Covid-19 Worldwide...

Available online 5 July 2020

We evaluated the impact of CMV managed with preemptive therapy (PET) on healthcare resource utilization after hematopoietic cell transplantation (HCT) at a single center.

In multivariable models CMV managed by PET was associated increased number of readmissions and inpatient cost.

CMV-related readmissions were associated with increased length of stay (LOS) and cost compared to non CMV-related readmissions.

CMV viremia occurs in 40%-80% of CMV seropositive (R+) allogeneic hematopoietic stem cell (HCT) recipients. The preemptive therapy (PET) strategy has reduced the risk of CMV end-organ disease (EOD) and associated mortality but may lead to substantial healthcare resource utilization (HCRU) and cost. Real-world data on the economic impact of PET is relevant for the evaluation of alternative strategies for CMV management. We examined the impact of clinically significant CMV treated with PET on inpatient length of stay (LOS), number of readmissions and associated costs from day (D) 0 through D 180 post-HCT.

A retrospective study of CMV seropositive (R+) adults who underwent peripheral blood or marrow allogeneic HCT from March 2013 through December 2017 at Memorial Sloan Kettering Cancer Center. Patients were routinely screened for CMV by quantitative PCR and received PET per institutional standards of care. Data was extracted from electronic medical records and hospital databases. Itemized cost data per patient was obtained from the Vizient database adjusted to 2017 dollars using inflation indices. Study outcomes included healthcare resource use (HCRU) evaluated by inpatient LOS and inpatient cost in patients who received PET for clinically significant CMV (PET group) compared to those who did not receive PET (no PET group); and frequency and cost of CMV-related compared to non-CMV-related readmissions. We utilized multivariable negative binomial and log-linked Gamma models to examine the incremental healthcare resource use and cost associated with PET controlling for other potential factors.

Of 357 patients included in the analyses, PET was initiated in 208 (56.5%) at a median of 35 days after HCT. By D180, 23 patients (6.4%) developed CMV EOD and three (0.8%) died of CMV. PET recipients had a longer LOS for HCT admission (p=0.0276) and total LOS by D 180 (p=0.0001), higher number of readmissions (p=0.0001), higher mean inpatient cost for HCT admission ($189,389 vs. $151,646, p=0.0133) and total inpatient cost by D180 ($297,563 vs. $205,815, p<0.0001) compared with no PET recipients. Among PET recipients, CMV-related readmissions were associated with higher mean cost per episode compared to non CMV-related readmissions ($165,455 vs. $89,419, p=0.005). CMV-related readmissions comprised of 40.6% of total all-cause readmissions and incurred 55.9% of total all-cause readmission cost in PET recipients.

HCT recipients who had CMV infection treated with the currently available PET had a greater inpatient HCRU including LOS and cost by D 180 compared with patients who did not receive PET. The cost of CMV-related readmissions accounted for 60% of total readmission cost among PET recipients. Future studies are needed to examine the cost-effectiveness of alternative strategies for CMV management.

Hematopoietic cell transplantation (HCT)

cytomegalovirus (CMV)

preemptive therapy (PET)

readmission

healthcare resource utilization (HCRU)

inpatient cost

Recommended articlesCiting articles (0)

2020 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy

Go here to see the original:
Impact of preemptive therapy for Cytomegalovirus on ...

Some 8.7 million years ago, much of what is now Idaho was torched by clouds of hot volcanic ash, destroying all vegetation and animals in sight. The supervolcano, Yellowstone, was erupting. This was Yellowstones largest eruption on record.

Super-eruptions can decimate entire regions, and their cocktail of ash and gases can alter the climate.But, even though they eject huge amounts of material, there are very few documented super-eruptions in the geologic record. So we dont fully understand why they are so big or how often they occur. Now, details of the Yellowstone supervolcanic eruption are documented in a new study published in the journal Geology.

Yellowstones ancient eruptions scattered volcanic debris across the northwestern US. There are so many deposits covering an area tens of thousands of square kilometers that it can be difficult to tell each eruption apart. To get around this, volcanologists collected detailed identifying information, including chemical and chronological data, on each geological deposit.

Volcanic ash from Yellowstone

Wikimedia

When they looked at the data, they found that much of the volcanic debris, which was thought previously to come from repeated smaller eruptions, had the same chemical makeup and age. In fact, these deposits were produced by two previously unrecognized super-eruptions. Both eruptions were searingly hot, and would have baked the landscape in a thick coating of molten volcanic glass. The youngest of the two, known as the Greys Landing super-eruption, is dated to roughly 8.7 million years ago, and, according to the volume of debris released, is 30% larger than all other eruptions recorded from Yellowstone.

Recognition of these events brings Yellowstone's total number of eruptions during the late Miocene to six. That makes for one eruption about every 520,000 years. Since then, however, the pace of eruptions has slowed to once every 1.5 million years.

The evidence seems to suggest that Yellowstone is slowing down. And if this trend continues, the next super-eruption won't happen for another 900,000 years. Predicting eruptions is however a risky business, and the United States Geological Survey still maintain a permanent monitoring network on Yellowstone just in case.

Go here to see the original:
The US is deporting scientists. I'm one of them - Massive Science